BioPharma « Terug naar discussie overzicht

HIV; waarom lager?

1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 52 53 54 55 56 57 58 59 60 61 62 ... 70 71 72 73 74 » | Laatste

Omlaag ↓

[verwijderd] 18 augustus 2007 09:44

heb er niet zoveel verstand van, wat staat hier nou eigenlijk?

[verwijderd] 18 augustus 2007 21:44

quote:
GhosTWolF schreef:
heb er niet zoveel verstand van, wat staat hier nou eigenlijk?

correct me if I am wrong, maar volgens mij zit het als volgt in elkaar:

Op 29 maart heeft Calypte een financiering afgesloten met een groep investeerders, er zijn toen 100 miljoen aandelen geissued tegen een koers van 0,052 en er zijn afspraken gemaakt voor warrents exercisable binnen 18 maanden. Voor de issued aandelen heeft Calypte 5,2 mijoen gehad (geld wat hard nodig was, om door te kunnen). De warrents kunnen nog eens maximaal 13,5 miljoen opleveren. Wat Calypte nu wil (lees wat die investeerders nu willen) zijn die aandelen registeren voor een eventuele resale (aan andere investeerders) zodat ook zij kunnen cashen.

Ze hebben eerst geprobeerd gelijk 286 miljoen stukken te registeren (dus de 116 mijoen al geissuede en de 168 miljoen voortkomend uit warrents) met een maximale verkoopprijs van 0,09475 (koers deed toen 0,07-0,09). Op 10 mei is dit door de SEC afgewezen, aangezien dit niet in het belang van de andere aandeelhouders was.

Vervolgens is Calypte met een pb-offensief gekomen, met als resultaat de koers rond de 0,12-0,14. Ze hebben toen een registratie bij de SEC ingediend om de al geissuede 116 miljoen te laten registeren tegen een maximale verkoopprijs van 0,138. Ook dit is nu afgewezen, ook omdat dit niet in het belang van de aandeelhouders is.

Voorlopig kunnen de 116 miljoen dus niet voor resale aangeboden worden, vraag is denk wel wat hierover is afgesproken tijdens de financiering? Ik kan me voorstellen dat de investeerders wel willen cashen, immers onzekerheid over voortbestaan blijven om de hoek liggen, zo lang de omzet niet drastisch gaat stijgen.

Misschien komt er wel weer een charme-offensief om de koers opnieuw hoger te krijgen, echter krijgen ze de stukken dan wel geregistreerd bij de SEC? Investeerders kunnen niet zomaar 116 miljoen stukken op de markt kwijt, dus ze moeten iest proberen om van hun stukken af te komen.

Kortom er blijven veel vraagtekens. Blijft erg boeiend om te zien wat er gaat gebeuren..

[verwijderd] 21 augustus 2007 23:54

Van het Yahoo board :

Lets hope that THIS is not what is holding up approval of Calypte's rapid test in China.

Must have clean air and put forth great image - all in time for olympics.

"BEIJING — Wary of exposing China's flaws to the news media's glare before next year's Olympic Games, authorities are cracking down on groups that help AIDS victims and orphans, shuttering their offices and banning meetings and other gatherings. In one case, an activist in Henan province, where the nation's AIDS crisis hit early, said police ordered him out of his office on Thursday and suggested that he flee the area for his own safety. Six other volunteers in the group were detained.

"They said our organization was illegal and our activities were illegal," said Zhu Zhaowu of the China Orchid AIDS Project's office in Kaifeng in central Henan province.

Police in the same city barred a conference for AIDS activists that had been scheduled for Aug. 19-20 by another nonprofit group known as Grassroots.

Police pulled the plug earlier this month on two other AIDS conferences in the southern city of Guangzhou — one that was to bring legal scholars from three continents and another at Sun Yatsen University .

The repression perplexes foreign experts seeking to help China grapple with the rising challenges of combating HIV infection.

"Nothing about it makes any sense," said Meg Davis , director of Asia Catalyst, a New York -based group and co-sponsor of the canceled Guangzhou legal conference.

" China is at a crossroads both in terms of its fight against AIDS and its very new and fragile civil society," Davis said.

Some domestic activists said China's leaders are clamping down because they worry that international media attention in the run-up to next summer's Olympic Games will focus on aspects of China that leaders find embarrassing.

"They hope that there will be no unharmonious voices during the Olympics period," said Hu Jia , an activist and co-founder of a nonprofit Beijing AIDS group.

Legal experts said the crackdown could backfire on China's efforts to combat HIV infection.

"If you suppress human rights, what happens is that people vulnerable to HIV are scared to be tested or seek treatment," said Mark Heywood , founder of South Africa's AIDS Law project and chairman of the UNAIDS human rights reference group, a body offering advice on the global epidemic.

Heywood, who was to attend the Aug. 3-4 Guangzhou conference, said China "is getting away with paying lip service to how we should deal with AIDS, but on the ground it is doing something completely different."

China appears to have averted the large-scale AIDS epidemic that has hit Thailand and parts of Sub-Saharan Africa. Official statistics say the nation of 1.3 billion people has 650,000 people infected with the virus.

The virus has primarily hit drug users, sex workers, ethnic minorities and migrant workers. Henan province in central China became a hotspot in the 1990s when brokers known as "blood heads" paid farmers for blood and plasma, which they sold to unsanitary, often state-run, clinics and hospitals

tinyurl.com/2a5c7z

[verwijderd] 22 augustus 2007 12:39

Van Ihub :

The delay in SFDA approval might be China`s insistence of dual-purpose STD testing. I have a slightly different perspective of Cato`s numbers in that it wasn`t last January that I expected SFDA approval but the January before. I see the analyst (Gregozeski, William of Capstone Investments) has lowered his estimates for `07 revenue to $2.52m from $3.5m a couple of weeks ago, although he is still bullish enough to call for $22m in `08.

investorshub.advfn.com/boards/read_ms...

[verwijderd] 22 augustus 2007 16:08

quote:
nudie schreef:
[quote=GhosTWolF]
heb er niet zoveel verstand van, wat staat hier nou eigenlijk?
[/quote]
correct me if I am wrong, maar volgens mij zit het als volgt in elkaar:

Op 29 maart heeft Calypte een financiering afgesloten met een groep investeerders, er zijn toen 100 miljoen aandelen geissued tegen een koers van 0,052 en er zijn afspraken gemaakt voor warrents exercisable binnen 18 maanden. Voor de issued aandelen heeft Calypte 5,2 mijoen gehad (geld wat hard nodig was, om door te kunnen). De warrents kunnen nog eens maximaal 13,5 miljoen opleveren. Wat Calypte nu wil (lees wat die investeerders nu willen) zijn die aandelen registeren voor een eventuele resale (aan andere investeerders) zodat ook zij kunnen cashen.

Ze hebben eerst geprobeerd gelijk 286 miljoen stukken te registeren (dus de 116 mijoen al geissuede en de 168 miljoen voortkomend uit warrents) met een maximale verkoopprijs van 0,09475 (koers deed toen 0,07-0,09). Op 10 mei is dit door de SEC afgewezen, aangezien dit niet in het belang van de andere aandeelhouders was.

Vervolgens is Calypte met een pb-offensief gekomen, met als resultaat de koers rond de 0,12-0,14. Ze hebben toen een registratie bij de SEC ingediend om de al geissuede 116 miljoen te laten registeren tegen een maximale verkoopprijs van 0,138. Ook dit is nu afgewezen, ook omdat dit niet in het belang van de aandeelhouders is.

Voorlopig kunnen de 116 miljoen dus niet voor resale aangeboden worden, vraag is denk wel wat hierover is afgesproken tijdens de financiering? Ik kan me voorstellen dat de investeerders wel willen cashen, immers onzekerheid over voortbestaan blijven om de hoek liggen, zo lang de omzet niet drastisch gaat stijgen.

Misschien komt er wel weer een charme-offensief om de koers opnieuw hoger te krijgen, echter krijgen ze de stukken dan wel geregistreerd bij de SEC? Investeerders kunnen niet zomaar 116 miljoen stukken op de markt kwijt, dus ze moeten iest proberen om van hun stukken af te komen.

Kortom er blijven veel vraagtekens. Blijft erg boeiend om te zien wat er gaat gebeuren..

spijt me voor de late reactie, maar bedankt voor je uitleg!

[verwijderd] 27 augustus 2007 11:11

Financials :

finance.yahoo.com/q/is?s=cbmc.ob

Ziet er niet goed uit. Ze zullen nog hard moeten knokken om de verwachtingen voor 2007 waar te maken.

[verwijderd] 27 augustus 2007 13:29

quote:
Jommeke schreef:
Financials :

finance.yahoo.com/q/is?s=cbmc.ob

Ziet er niet goed uit. Ze zullen nog hard moeten knokken om de verwachtingen voor 2007 waar te maken.

Cijfers waren toch al bekend of zijn deze cijfers anders dan pb 2 weken geleden?

[verwijderd] 27 augustus 2007 13:45

quote:
nudie schreef:
[quote=Jommeke]
Financials :

finance.yahoo.com/q/is?s=cbmc.ob

Ziet er niet goed uit. Ze zullen nog hard moeten knokken om de verwachtingen voor 2007 waar te maken.
[/quote]
Cijfers waren toch al bekend of zijn deze cijfers anders dan pb 2 weken geleden?

Sorry nudie, ben pas terug uit vakantie en heb nog wat in te halen.:)

[verwijderd] 28 augustus 2007 14:10

Press Release
Republic of Kenya Adopting New HIV Self Testing Program
Policy Promotes Oral Fluid Testing
LAKE OSWEGO, Ore., Aug 28, 2007 (BUSINESS WIRE) -- Calypte Biomedical Corporation (OTCBB: CBMC), a manufacturer of medical diagnostic tests for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today its support for the guidance policy unveiled last week by the National AIDS Control Council (NACC) of Kenya gives Kenyans personal control over their HIV testing and encourages them to use non-invasive tests such as HIV-1/2 OMT (oral fluid) rapid tests. Calypte has provided Kenya, through the National AIDS and STD Control Program (NASCOP) of the Ministry of Health, 10,000 Aware(R) HIV-1/2 OMT (oral fluid) rapid tests which will be available to the public.
"An important facility or tool (is) to identify who needs to be treated - the sooner the better - and thereby making an important contribution to the fight against HIV/AIDS," His Excellency Peter Ogego, Kenyan Ambassador to the United States, noted at the time of accepting of Calypte OMT kits while in Washington DC..

Mr. Roger I. Gale, Calypte's Chairman and Chief Executive Officer commented, "The Republic of Kenya is now expanding its HIV/AIDS testing, which up to now has been blood-based testing, with the availability of simple, accurate non-invasive tests such as our Aware(R) HIV-1/2 oral fluid rapid tests. Testing is the best way to identify people living with HIV/AIDS who need to enter treatment or intervention programs. The Kenyan government provides access to antiretroviral drugs to people living with HIV/AIDS at no-cost, and we are pleased to be associated with the continuing improvement in the HIV situation in Kenya."

Professor Alloys S.S. Orago, Director of NACC Kenya, recently at a press conference in Nairobi said that Kenya is one of three African nations that recently have made significant progress in HIV/AIDS prevention and treatment programs. Professor Orago said, "These (Kenyan AIDS) figures illustrate the magnitude of the inherent task in providing prevention, treatment, care and support services to ensure universal access." NASCOP is involving 10,000 people in the pilot phase of an evaluation project using the Calypte oral fluid rapid test kits.

Oral fluid testing is expected to come into general use in Kenya by the end of this year when a government policy directive is released.

About Kenya:

According to the December 2006 AIDS Epidemic Update, published jointly by the Joint United Nations Programme on HIV/AIDS ("UNAIDS") and the World Health Organization, approximately 1.3 million people in Kenya live with AIDS. "Kenya is still contending with a serious AIDS epidemic despite evidence of declining HIV prevalence." National adult HIV prevalence fell from 10% in the late 1990s to just over 6% in 2005.

The country recorded 55,000 new HIV cases in 2006, compared with 85,000 in 2004. HIV prevalence in urban areas is about 8.3%, compared with 4% in rural areas. In addition, deaths from AIDS-related causes decreased from 120,000 in 2003 to 85,000 in 2006.

About Calypte Biomedical:

Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(R) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.

SOURCE: Calypte Biomedical Corporation

phx.corporate-ir.net/phoenix.zhtml?c=...

[verwijderd] 28 augustus 2007 15:22

Van Ihub :

What I like even more is those that ran the short interest up over 6900% (08/24/2007 17:32 ET - CBMC: Short Interest UP 6913.6% to 140.3K in Aug 2007 - Knobias ) are going to drive up the price today.
Just my opinion. I've been wrong before. I am happy for us all!

[verwijderd] 28 augustus 2007 15:57

weinig aktie tot nu toe,12100 stuks omzet met een plusje van 8 %

[verwijderd] 28 augustus 2007 16:08

quote:
vlielander schreef:
weinig aktie tot nu toe,12100 stuks omzet met een plusje van 8 %

Ja, valt tegen. Al wat er komt zijn beloftes, maar geen feiten. De HIV markt is nochtans groot genoeg. Is het dan zo moeilijk om een omzet te halen ? Het lijkt wel of die landen zijn gaan berusten in het feit dat de bevolking HIV heeft.
Uiteindelijk zal het China nieuws ( als dat ooit komt ) nog de enige trigger zijn.

[verwijderd] 31 augustus 2007 20:44

Healthplex Expo 2007 in China

www.healthplex.com.cn/health_en/ewszh...

Looks like BMBPC, Ltd. recently attended an expo in China to showcase the Aware test

Beijing MARR Bio -Pharmaceutical Co., Ltd. was established in Beijing in 2005 to bring the Aware™ OMT test to China. The company acquired manufacturing facilities in Huairou with a planned production capacity of up to 100 million HIV rapid tests per year and is in the process of registering the Aware™ OMT test in China.

[verwijderd] 5 september 2007 15:56

Calypte Opens Dubai Office
Wednesday September 5, 9:48 am ET
New Location to Drive Growth Throughout Middle East and Northern Africa

LAKE OSWEGO, Ore.--(BUSINESS WIRE)--Calypte Biomedical Corporation (OTCBB: CBMC - News), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced today that it has established a branch office in Dubai, United Arab Emirates (UAE) as the Company's regional focal point for its Middle East and Northern Africa ("MENA") operations.

The Dubai Office intends to work with Governmental and Non-Government Organizations ("NGO's") having headquarters or representation in the region in their efforts to control the AIDS epidemic by promoting the use of Calypte's products, especially its non-invasive Aware® HIV-1/2 OMT (oral fluid) rapid test.

Ms. Manahel Thabet, newly appointed President of the Dubai Office, completed her post graduate studies in Commerce in 1996 prior to joining the United Nations. She spent eight years with several NGO's in the MENA region before serving as an Investment Advisor for the largest bank in the UAE for two years. More recently she has run a fund management company.

Mr. Ravi Pandit has been appointed Vice President and will support Ms. Thabet efforts. He has been the Managing Partner of a general trading company in Dubai for the past two years. Prior to that, Mr. Pandit worked for 15 years with the New Medical Centre Group of Companies, where his last assignment was to head the global money transfer brand of the Group Company, UAEXCHANGE. Prior to that, he worked for 10 years in management positions with India's largest Bank, State Bank of India, in both India and the UAE.

"We believe Dubai is an excellent location from which to expand our Middle Eastern and North African operations," said Roger I. Gale, Calypte's Chairman and Chief Executive Officer. "Manahel and Ravi each have extensive background in and knowledge of this region and their many contacts make them a strong addition to the Calypte team."

Ms. Thabet noted, "In its continuing endeavor to establish a global presence, I am pleased to join Calypte to launch its newest branch office in Dubai. Located at the cross roads between East and West, in my opinion Dubai hails as one of the best strategic locations in the world today, being situated as a time zone bridge between both the Far East and Europe and the Commonwealth of Independent States (C.I.S.) and Africa. It is a gateway to the more than 1.5 billion people in the region. In my opinion, the expanding needs of Calypte can be effectively met by the office in Dubai with its unrivaled accessibility to so much of the world."

Ms. Thabet continued, "My objective is to use this office to enable Calypte to leverage its sales and marketing efforts in this region where many of the governments have recently awakened to the stark reality that the HIV/AIDS epidemic is spreading in their countries. Governments and NGO's in these regions are allocating substantial funds to control the HIV/AIDS."

P.

[verwijderd] 5 september 2007 17:47

weinig impact dit nieuws,volume ook bedroevend laag

[verwijderd] 7 september 2007 21:41

Bedenking op Ihub :

As you know, I have been one of the harshest critics of Calypte's management. However, even I see the positives at Calypte and hope that they can make a success of the company, more for the benefit of mankind, than just for the profits of a small OTC company owned primarily by foriegners.

Positives of Calypte

1. Have a rapid oral test that works. Tests and approvals in many countries have shown this to be true.

2. Calypte's rapid tests at this point have more approvals and seemingly a cheaper price than Orasure its only rival with an oral rapid test.

3. Rapid oral tests are safer than rapid blood tests, for both testors and testees.

4. The rapid oral tests are more efficient to process in most cases than rapid blood tests.

5. The tests have an 18 month shelf life, better than their competitors and long enough for overseas usages.

Calypte's biggest challenge will be to leverage these advantages into sales. So far the less costly rapid blood tests, also regarded internationally as the "gold standard test", have been the winner in just about all sales situation.

Things Calypte should do. (In my opinion)

1. Receive approval in Thailand of their rapid oral test. All of the rapid oral tests presently sold are manufactured in Thailand, by a contactor manufacturer. The fact that Thailand has not yet approved the test and seemingly that Calypte has not even applied for approval is a BLACK MARK on Calypte. This is especially bad because many countries will not approve a test that is not approved in country of mannufacture. So not having Thailand approval is also preventing approval in other countries. This would seem a simple thing to do, yet it hasn't been done. Yet.

2. Get WHO approval for their rapid oral tests. Many many countries buy their rapid HIV tests from the approved tests on the WHO bulk purchasing program. Calypte has not yet been added to this list. Why?

3. Approval in China of both the rapid oral test and the manufacturing plant. Even I am amazed that this hasn't occurred long ago.

4. Lower costs on rapid oral tests. Easier said than done I know, especially at low volume. However one must ask why rapid blood tests can be sold for $ .49 - $ .75 and rapid oral tests are sold for $ 1.50 - $ 5.00. What justifies the higher cost?

5. Find niche markets that can appreciate the increased safety and convenience of the oral test even at a slightly higher price. While obvious this has not yet materialized yet. (Hopefully the new hires and offices will help find these situations)

6. Have Roger Gale call Bill and Melinda Gates in nearby Seattle schedule a meeting with them and tell them the Calypte advantages and ASK them what Calypte could do to help eridicate HIV/AIDS worldwide with their products. Bill Gates, with his influence in the Bill and Melinda Gates Foundation, could do more for Calypte than any one single person in the world. Yet we have heard nothing about any efforts in that area.

In addition it would be nice to see Roger Gale and rest of the management team to limit their total combined salaries to no more than 25% of annual sales. This might convince investors and people like Bill Gates that the company is something more than a self enrichment "penny stock play" by management.

So in a nutshell.

Believe that Calypte has a product that works and is needed in worldwide effort to eradicate AIDS/HIV. YES.

Believe that management has failed to do mauch of what they could do to to make the oral test a success. YES

[verwijderd] 7 september 2007 22:11

Ach Jom, als hij verstand had van het runnen van zo'n bedrijf, dan zou hij wel ergens CEO zijn.

Dus niet.

Psycho
alles in zijn perspectief

[verwijderd] 7 september 2007 22:16

quote:
psycho-pharma schreef:
Ach Jom, als hij verstand had van het runnen van zo'n bedrijf, dan zou hij wel ergens CEO zijn.

Dus niet.

Psycho
alles in zijn perspectief

:) Heb jij ze nog altijd psycho ?

[verwijderd] 7 september 2007 22:23

Yessssssssssssssirrrrrjomm

Sidney or the bush!!!!!!!

....... 100K

Psycho

[verwijderd] 11 september 2007 21:41

Ik heb het gevoel dat ze hem stilaan hoger willen manipuleren. Spijtig dat het volume zo laag is. Maar wie weet..misschien worden die anderen wakker ?

1.470 Posts, Pagina: « 1 2 3 4 5 6 ... 52 53 54 55 56 57 58 59 60 61 62 ... 70 71 72 73 74 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

AEX 904,21 -7,13 -0,78% 16:52


Germany40^	22.637,00	-1,62%
BEL 20	4.365,20	-2,33%
Europe50^	5.393,86	-1,36%
US30^	42.343,30	-1,06%
Nasd100^	19.594,60	-2,94%
US500^	5.655,87	-1,95%
Japan225^	36.533,20	-2,01%
Gold spot	2.905,32	-0,16%
EUR/USD	1,0826	-0,21%
WTI	66,51	-0,72%